Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration

– Zeno granted BTD for the treatment of NRG1+ non-small cell lung cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 05, 2023 -- Merus N.V. , a clinical-stage oncology company...

Related Keywords

Netherlands ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American , ,Drug Administration ,Exchange Commission ,Early Access Program ,Linkedin ,Twitter ,American Society Of Clinical Oncology Annual Meetings ,Breakthrough Therapy Designation ,Fast Track Designation ,Orphan Drug Designation ,Clinical Oncology Annual Meetings ,Biologics License Application ,Bill Lundberg ,Chief Executive Officer ,Merus Dock ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,